Can pulsed ultrasound be used to treat erectile dysfunction, and what is the recommended protocol?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Low-Intensity Pulsed Ultrasound (LIPUS) for Erectile Dysfunction

LIPUS can be used to treat mild to moderate erectile dysfunction with a protocol of twice weekly treatments for 4 weeks (8 total sessions), though the 2025 EAU guidelines do not yet include it as a standard recommendation, noting that standardized protocols are still lacking. 1

Current Guideline Status

The most recent major guidelines acknowledge LIPUS as an emerging therapy but stop short of formal recommendations:

  • The 2025 EAU guidelines mention that innovative treatments like LIPUS are "currently under investigation, requiring further large-scale, placebo-controlled studies for clinical validation" 1
  • Neither the 2025 EAU nor 2018 AUA guidelines 2 include LIPUS in their formal treatment algorithms
  • LIPUS is not FDA-approved for ED treatment in the United States

Evidence-Based Protocol

Based on the highest quality clinical trial data, the recommended protocol is:

Treatment Parameters:

  • Frequency: Twice weekly for 4 consecutive weeks (total of 8 sessions) 3, 4
  • Application sites: Both sides of the penis shaft and crus
  • Duration: 5 minutes per treatment area
  • Total treatment time: Approximately 20 minutes per session

A large randomized trial (n=323) demonstrated that three times weekly treatment showed equivalent efficacy to twice weekly, providing flexibility based on patient preference 3. However, twice weekly remains the standard based on the original sham-controlled trial.

Clinical Efficacy

The most robust evidence comes from a 2019 multicenter, randomized, double-blind, sham-controlled trial (n=120):

  • Response rate: 67.5% in LIPUS group vs. 20% in sham control at 12 weeks 4
  • IIEF-5 improvement: Significant increases maintained through 12-week follow-up
  • Successful intercourse (SEP-3): 73% at 12 weeks vs. 29% in controls 4

Important caveat: A 2026 systematic review noted that while some trials show benefit, evidence remains "mixed and inconsistent," with methodological concerns including inadequate MCID reporting and heterogeneous protocols 5. This limits confidence in definitive efficacy claims.

Patient Selection

LIPUS appears most effective for:

  • Mild to moderate ED (primary indication) 3, 4
  • Severe ED without comorbidities when combined with PDE5 inhibitors 6
  • Patients seeking non-invasive alternatives to oral medications

Combination Therapy

For severe ED or PDE5i non-responders, LIPUS should be combined with daily tadalafil (10 mg) rather than used as monotherapy 6. A 2024 retrospective study showed:

  • Effective rate in severe ED without comorbidities: 66.67% with LIPUS + tadalafil vs. 36% with LIPUS alone at 12 weeks 6
  • Synergistic effects particularly evident in patients without diabetes or other comorbidities

Safety Profile

LIPUS demonstrates excellent safety with no treatment-related adverse events reported across multiple trials 3, 4:

  • No local petechiae, ecchymosis, or hematuria
  • No pain or discomfort during treatment
  • No systemic side effects
  • Safe for patients on anticoagulation (unlike vacuum erection devices which require caution) 2

Mechanisms of Action

LIPUS works through multiple regenerative pathways 7:

  • Upregulating endothelial and neuronal nitric oxide synthase
  • Increasing smooth muscle and endothelial content
  • Inhibiting cavernosal fibrosis
  • Improving cavernous nerve repair
  • Reducing oxidative stress

Clinical Implementation Considerations

Key limitations to address with patients:

  1. Not guideline-endorsed: Remains investigational per major urological societies 1, 2
  2. Cost and availability: Not FDA-approved; limited availability in clinical practice
  3. Long-term efficacy unknown: Most studies report only 12-week outcomes 5
  4. Protocol variability: Lack of standardization across studies limits generalizability 1, 5

Treatment Algorithm Position

Based on current evidence and guidelines:

  1. First-line: PDE5 inhibitors remain the standard 1, 2
  2. Second-line consideration: LIPUS may be offered for mild-moderate ED in motivated patients seeking non-pharmacologic options
  3. Combination approach: Consider LIPUS + daily PDE5i for severe ED without comorbidities 6
  4. Not recommended: As monotherapy for severe ED with multiple comorbidities

The 2025 EAU guidelines explicitly state that low-intensity shockwave therapy (a related technology) "may be used in men with mild vasculogenic ED" but note this is a weak recommendation 1. LIPUS should be positioned similarly until stronger evidence emerges.

References

2
Guideline

erectile dysfunction: aua guideline.

The Journal of urology, 2018

Related Questions

Is a 412‑Hz ultrasound effective for improving penile blood flow in erectile dysfunction?
Is the men's pelvic pulse device effective for improving erectile function in men?
How should I evaluate and manage a 57-year-old male with normal laboratory values who has had low libido and difficulty becoming aroused for six months?
Can lorazepam (generic name lorazepam) cause erectile dysfunction in adult males?
As a chronic masturbator with erectile dysfunction, can lifestyle modifications alone (without pharmacotherapy) restore normal erectile function?
What is the Zio XT cardiac monitor?
Which test should be performed to detect bloodstream infection (septicemia) in a febrile patient?
Should Romiplostim be used for thrombocytopenia in a patient with sepsis, and what are the appropriate indications, dosing, and monitoring recommendations?
What newer oral anticoagulants are preferred for this patient?
What oral step‑down therapy is appropriate for a patient with an ESBL‑producing urinary tract infection after completing 5 days of Zerbaxa (ceftazidime‑avibactam)?
What is the appropriate dosing schedule for a 12‑day prednisone (10 mg) dose‑pak?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.